Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Trial Profile

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs KRT 232 (Primary) ; Ruxolitinib
  • Indications Polycythaemia vera
  • Focus Therapeutic Use
  • Sponsors Kartos Therapeutics
  • Most Recent Events

    • 17 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Oct 2018 to 31 Jan 2018.
    • 19 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top